Clinical trial
Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major…
NCT00411099 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00411099 |
|---|---|
| Title | Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder |
| Official title | An 8-week, Randomized, Double-blind, Fixed Dosage, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy, Safety and Tolerability of Agomelatine 25 mg and 50 mg in the Treatment of Major Depressive Disorder (MDD) Followed by a 52-week, Open-label Extension (CAGO178A2301E) |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Major Depressive Disorder |
| Intervention type | Drug |
| Interventions | agomelatine, placebo |
| Enrollment | 508 |
| Start date | Dec 1, 2006 |
| Primary completion | Jan 1, 2008 |
| First posted | Dec 13, 2006 |
| Last update posted | Dec 23, 2020 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: